Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 We Should Treat Financial Toxicity With Curative, Rather Than Palliative, Intent.

Literature DB >> 34546800

We Should Treat Financial Toxicity With Curative, Rather Than Palliative, Intent.

Aaron P Mitchell¹.

Abstract

Entities: Chemical

Mesh：

Year: 2021 PMID： 34546800 PMCID： PMC9213194 DOI： 10.1200/OP.21.00540

Source DB: PubMed Journal: JCO Oncol Pract ISSN： 2688-1527

Keyword Cloud
References

× No keyword cloud information.

11 in total

1. Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics.

Authors: Aaron Mitchell; Benyam Muluneh; Rachana Patel; Ethan Basch
Journal: J Oncol Pharm Pract Date: 2017-07-17 Impact factor: 1.809

2. Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach.

Authors: S Yousuf Zafar; Jeffrey Peppercorn; Akwasi Asabere; Alex Bastian
Journal: J Oncol Pract Date: 2017-01-31 Impact factor: 3.840

3. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.

Authors: Jalpa A Doshi; Pengxiang Li; Hairong Huo; Amy R Pettit; Rishab Kumar; Brenda M Weiss; Scott F Huntington
Journal: Am J Manag Care Date: 2016-03 Impact factor: 2.229

4. Use of Charity Financial Assistance for Novel Oral Anticancer Agents.

Authors: Adam J Olszewski; Andrew R Zullo; Christopher R Nering; Justin P Huynh
Journal: J Oncol Pract Date: 2018-02-13 Impact factor: 3.840

5. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.

Authors: Aaron N Winn; Nancy L Keating; Stacie B Dusetzina
Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544

6. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.

Authors: Angelina Y Jeong; Eric B Schwartz; Andrea R Roman; Rachel L McDevitt; Mary K Oerline; Elyssa Henry; Christine M Veenstra; Megan E V Caram
Journal: JCO Oncol Pract Date: 2021-09-07

We Should Treat Financial Toxicity With Curative, Rather Than Palliative, Intent.

1. Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics.

2. Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach.

3. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.

4. Use of Charity Financial Assistance for Novel Oral Anticancer Agents.

5. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.

6. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.

7. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.

8. Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer.

9. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.

10. Mortality due to cancer treatment delay: systematic review and meta-analysis.